| Malignant neoplasm of breast

Arimidex vs Herceptin Hylecta

Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.

Deep comparison between: Arimidex vs Herceptin Hylecta with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHerceptin Hylecta has a higher rate of injection site reactions vs Arimidex based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Herceptin Hylecta but not Arimidex, including UnitedHealthcare

Category

Arimidex

Herceptin Hylecta

At A Glance

RouteOral

FrequencyDaily

ClassAromatase inhibitor

RouteSC injection

FrequencyEvery 3 weeks

ClassHER2 antagonist

Indications

Malignant neoplasm of breast
Locally advanced breast cancer
Carcinoma breast stage IV

Malignant neoplasm of breast

Dosing

Malignant neoplasm of breast 1 mg tablet orally once daily; adjuvant treatment duration in the ATAC trial was 5 years.

Locally advanced breast cancer, Carcinoma breast stage IV 1 mg tablet orally once daily; continue until tumor progression.

Malignant neoplasm of breast 600 mg/10,000 units administered subcutaneously over approximately 2-5 minutes once every three weeks; no loading dose required; adjuvant patients treated for 52 weeks or until disease recurrence, metastatic patients treated until disease progression.

Contraindications

Hypersensitivity to anastrozole or any excipient (including anaphylaxis, angioedema, and urticaria)

—

Drug Interactions

918View drug interactions

1202View drug interactions

Adverse Reactions

Most common (>=10%) Hot flashes, asthenia, arthritis, pain, arthralgia, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, bone pain, peripheral edema, increased cough, dyspnea, pharyngitis, lymphedema

Serious Skin lesions, ulcers, or blisters; severe allergic reactions with swelling of face, lips, tongue, and/or throat; liver function abnormalities including hepatitis

Postmarketing Hepatobiliary events (increases in alkaline phosphatase, ALT, AST, gamma-GT, and bilirubin; hepatitis), erythema multiforme, Stevens-Johnson syndrome, angioedema, urticaria, anaphylaxis, myalgia, hypercalcemia, tendon disorders including tendon rupture and tendonitis

Most common (>=10%) Alopecia, nausea, administration-related reactions, neutropenia, diarrhea, asthenia, fatigue, vomiting, myalgia, decreased appetite, stomatitis, arthralgia, headache, rash, constipation, pyrexia, cough, anemia, dyspnea, peripheral sensory neuropathy, leukopenia, mucosal inflammation, hot flush, upper respiratory tract infection

Serious Neutropenia (Grade >=3), febrile neutropenia, leukopenia, left ventricular dysfunction, cardiomyopathy, pulmonary toxicity, hypersensitivity reactions

Postmarketing Administration-related reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome

Pharmacology

Anastrozole is a selective non-steroidal aromatase inhibitor that suppresses estrogen biosynthesis by blocking the aromatase enzyme, significantly lowering serum estradiol concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone formation.

Trastuzumab is a humanized IgG1 kappa monoclonal antibody that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC); hyaluronidase reversibly increases subcutaneous tissue permeability by depolymerizing hyaluronan to enhance systemic absorption of trastuzumab.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Arimidex